← All trials
NCT06419946
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 15, 2024
- Primary completion
- Dec 15, 2028
- Completion date
- Dec 15, 2031
- First posted
- May 17, 2024
- Last posted
- May 17, 2024
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Vastra Gotaland RegionLead sponsor
- Lund UniversityCollaborator
- Norwegian University of Science and TechnologyCollaborator
- Ryhov County HospitalCollaborator
- Gävle HospitalCollaborator
- Sorlandet Hospital HFCollaborator
- University of UlmCollaborator
- University of BergenCollaborator
- University of StavangerCollaborator
- Kalmar County HospitalCollaborator
- University of OsloCollaborator
- Orebro UniversityCollaborator
- Karolinska InstituteCollaborator
- Linkoping UniversityOfficial
- University of GothenburgCollaborator
- Aarhus UniversityCollaborator
- Karlstad UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.